Physician profile
Iradj Maany
NPI 1912005794
$2,571.10
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $226 · 2021: $24.73 · 2023: $357 · 2024: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $490.63 | 2019-2020 | |
| Abbvie INC. | $468.28 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $285.66 | 2019 | |
| Allergan, INC. | $226.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.27 | 2019-2020 | |
| Lundbeck LLC | $149.90 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $147.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $128.16 | 2019 | |
| Axsome Therapeutics, INC. | $119.70 | 2023 | Auvelity |
| Neos Therapeutics, LP | $91.54 | 2019-2020 | |
| Shire North American Group INC | $87.79 | 2019 | |
| Neurocrine Biosciences, INC. | $67.06 | 2019 | |
| Adlon Therapeutics L.P. | $52.39 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.73 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $17.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iradj Maany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.